Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
UPDATE 1-US FDA approves expanded use of Bristol's cancer cell therapy [Yahoo! Finance]
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results [Yahoo! Finance]